Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors

被引：1

作者：

Fujisawa, Y. ^{[1
]}

机构：

[1] Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki, Japan

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 179卷 / 01期

关键词：

D O I：

10.1111/bjd.16689

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：224 / 225

页数：2

共 3 条

[1] Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population [J].

Fujisawa, Y. ;

Yoshino, K. ;

Otsuka, A. ;

Funakoshi, T. ;

Fujimura, T. ;

Yamamoto, Y. ;

Hata, H. ;

Tanaka, R. ;

Yamaguchi, K. ;

Nonomura, Y. ;

Hirai, I. ;

Furudate, S. ;

Okuhira, H. ;

Imafuku, K. ;

Aoki, M. ;

Matsushita, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) :213-215

[2] Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use [J].

Lorente, D. ;

Mateo, J. ;

Templeton, A. J. ;

Zafeiriou, Z. ;

Bianchini, D. ;

Ferraldeschi, R. ;

Bahl, A. ;

Shen, L. ;

Su, Z. ;

Sartor, O. ;

de Bono, J. S. .

ANNALS OF ONCOLOGY, 2015, 26 (04) :750-755

[3]

Machet L, 2018, BRIT J DERMATOL, V179, P224, DOI 10.1111/bjd.16675

← 1 →